Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

2.79
+0.18006.90%
Post-market: 2.75-0.0400-1.43%19:55 EDT
Volume:1.05M
Turnover:2.90M
Market Cap:134.78M
PE:-1.91
High:2.80
Open:2.61
Low:2.61
Close:2.61
Loading ...

Cassava Sciences Inc - Company to Pay Yale up to $4.5 Million in Milestones

THOMSON REUTERS
·
27 Feb

Cassava Sciences Inc - Enters License Agreement With Yale University

THOMSON REUTERS
·
27 Feb

Cassava Sciences Inc - Granted Exclusive Worldwide Rights to Yale's Patent Interests

THOMSON REUTERS
·
27 Feb

Cassava Sciences Licenses Simufilam Method of Treatment Patent

GlobeNewswire
·
27 Feb

Cassava Gears Up to Report Q4 Earnings: What's in the Cards?

Zacks
·
21 Feb

Clinical trials site shows Cassava Sciences REFOCUS-ALZ trial terminated

TIPRANKS
·
05 Feb

Cassava Sciences to Reduce Staff, Halt Further Analysis

MT Newswires Live
·
08 Jan

BRIEF-Cassava Sciences Provides A Business Update

Reuters
·
08 Jan

Cassava Sciences Inc: in Final Stages of Discontinuing Refocus-Alz Study

THOMSON REUTERS
·
08 Jan

Cassava Sciences Provides a Business Update

THOMSON REUTERS
·
08 Jan

Cassava- Topline Data From Phase 3 Refocus-Alz Study of Simufilam in Patients With Mild-to-Moderate Alzheimer's Disease Expected Late Q1/Early Q2 2025

THOMSON REUTERS
·
08 Jan

Cassava Sciences Inc: Implementing Cost Curtailment Including a Workforce Reduction of Approximately 33%

THOMSON REUTERS
·
08 Jan

Cassava Sciences Provides a Business Update

GlobeNewswire
·
08 Jan

Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP

TIPRANKS
·
13 Dec 2024

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

Zacks
·
30 Nov 2024

A Post-Mortem on Cassava Sciences

Zacks
·
27 Nov 2024